<p>(<b>A</b>) COLO 320 DM cells were treated with a range of Oxaliplatin (0.005–0.1 mM) or 5-Fluorouracil (0.05–2 mM) concentrations to determine the inhibitory concentration of 25% (IC25) and 50% (IC50). (<b>B</b>) Cells from COLO 320 DM total population were pre-treated for 48 hours with 25 uM EPA or SA. Afterwards cells were exposed for 24 hours with Oxaliplatin (<i>IC25, 2.5 </i><i>uM; IC50, 10 </i><i>uM</i>) and 5 Fluorouracil (<i>IC25, 100 </i><i>uM; IC50, 1.5 </i><i>mM</i>). (<b>C</b>) CD133 (+) cells were magnetically sorted from the total population of COLO 320 DM and were pre-treated for 48 hours with 25 uM EPA or SA and then exposed for 24 hours to IC25 and IC50 of Oxaliplatin and 5-Fluorouracil. Results represent the mean ± SD o...
Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this ...
Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this ...
<p>Ht-29 cells were treated with increasing concentrations of oxaliplatin (1–300 µM) in the presence...
Adjuvant therapy has evolved to become the standard care of colon cancer, but the tumor capability o...
Adjuvant therapy has evolved to become the standard care of colon cancer, but the tumor capability o...
Adjuvant therapy in colorectal cancer has evolved to become the standard of care, whereas the tumor ...
Adjuvant therapy in colorectal cancer has evolved to become the standard of care, whereas the tumor ...
Treatment conditions are described in "Material and Methods". On day 3, cells were counted by trypan...
<p>The in vitro sensitivity was expressed as the T/C ratio, in which T is the total volume of living...
<p>A–C, MTS assay in HCT116 (<i>MLH1−/MSH3−</i>), HCT116+3 (<i>MLH1+/MSH3−</i>), and HCT116+3+5 (<i>...
<p>A) The effect of oxaliplatin on the viability of human colorectal cancer cells. Caco-2, SW1116 an...
BACKGROUND: Time-dependence of cisplatin (CDDP) and oxaliplatin (L-OHP) cytotoxic effects in A431 a...
Recently, evidence has accumulated that weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) with...
A) Dose-response curves of cell viability in the parental HCT116 cells, HCT116/OX-R4.3, and HCT116/O...
A) Dose-response curves of cell viability in the parental HCT116 cells, HCT116/OX-R4.3, and HCT116/O...
Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this ...
Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this ...
<p>Ht-29 cells were treated with increasing concentrations of oxaliplatin (1–300 µM) in the presence...
Adjuvant therapy has evolved to become the standard care of colon cancer, but the tumor capability o...
Adjuvant therapy has evolved to become the standard care of colon cancer, but the tumor capability o...
Adjuvant therapy in colorectal cancer has evolved to become the standard of care, whereas the tumor ...
Adjuvant therapy in colorectal cancer has evolved to become the standard of care, whereas the tumor ...
Treatment conditions are described in "Material and Methods". On day 3, cells were counted by trypan...
<p>The in vitro sensitivity was expressed as the T/C ratio, in which T is the total volume of living...
<p>A–C, MTS assay in HCT116 (<i>MLH1−/MSH3−</i>), HCT116+3 (<i>MLH1+/MSH3−</i>), and HCT116+3+5 (<i>...
<p>A) The effect of oxaliplatin on the viability of human colorectal cancer cells. Caco-2, SW1116 an...
BACKGROUND: Time-dependence of cisplatin (CDDP) and oxaliplatin (L-OHP) cytotoxic effects in A431 a...
Recently, evidence has accumulated that weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) with...
A) Dose-response curves of cell viability in the parental HCT116 cells, HCT116/OX-R4.3, and HCT116/O...
A) Dose-response curves of cell viability in the parental HCT116 cells, HCT116/OX-R4.3, and HCT116/O...
Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this ...
Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this ...
<p>Ht-29 cells were treated with increasing concentrations of oxaliplatin (1–300 µM) in the presence...